

5 March 2024

Histology and Histopathology

We are researching histology/ cellular pathology activity in NHS organisations and the use of locums and outsourcing to report these.

For the period April 1st to December 31st 2023, please provide the following information:

1. How many whole time equivalent histopathology consultants (as defined by being on the GMC specialist register for pathology) were employed by the authority at 31/12/2023.

The paid WTEs for December 2023 was 22.70 WTEs.

2. How many histology cases were reported in the following period, overall and by the following sub-specialties - April 1st to December 31st 2023,

- dermatology:	14,380
- gastro-intestinal:	20,437
- urology:	2634
- gynaecology:	7780
- breast:	2778
- thoracic:	513
- head and neck:	3217
- other:	4654
- total cases reported:	56,393

3. How many of the total cases given above were reported by a. consultants (or other medical staff) employed by the authority during their contract Programmed Activities or PAs.

b. consultants employed by the authority, being paid additional amounts over and above their salary for additional work.

c. locum consultants working for the authority

d. external reporting companies.

Please provide a total number of cases and the number reported by each of the following:

- Unilabs
- HCA Laboratories including their subsidiary Backlogs
- Source LD Path (previously Source Bioscience, and LD Path limited)
- Cellular Pathology Services Limited
- Diagnexia
- Digital Pathology Partners
- Cytel (including their subsidiary Pathognomics)

5 March 2024

- **Poundbury Cancer Institute**
- **Medica**
- **external reporting companies total**

The were 218 WLI sessions undertaken in-house consultants made between April 2023 and December 2023. The activity in these sessions are dependent on complexity and speciality as directed by GMC guidance.

There were no locums or agency employed in this time period.

Source Bioscience only has been used for the 9 month period ended 31 December 2023.

4. How much did the authority spend on each of the following during the period a. consultants (or other medical staff) employed by the authority during their contract Programmed Activities or PAs. (salary plus NI plus pension contribution) b. consultants employed by the authority, being paid additional amounts over and above their salary for additional work. c. locum consultants working for the authority d. external reporting companies. Please provide a total spend and the spend with each of the following:

- **Unilabs**
- **HCA Laboratories including their subsidiary Backlogs**
- **Source LD Path (previously Source Bioscience, and LD Path limited)**
- **Cellular Pathology Services Limited**
- **Diagnexia**
- **Digital Pathology Partners**
- **Cyted (including their subsidiary Pathognomics)**
- **Poundbury Cancer Institute**
- **Medica**
- **external reporting companies total**

The WLI payments paid to in-house consultants made between April 2023 and December 2023 were £109k.

There are no locums or agency costs for Cell Path Medical in 2023-24.

Source Bioscience for the 9 month period ended 31 December 2023 was £280k.